MyMD Regains Compliance with Nasdaq Minimum Bid Price Requirement
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that its Investigational New Drug (IND) application for a Phase 2 clinical trial of oral MYMD-1® as a treatment for rheumatoid arthritis (RA) was recently cleared by the U.S. Food and Drug Administration (FDA), and plans are underway for trial launch in the first quarter of 2024.
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-? Market Disrupter, at BioFuture 2023
MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
MyMD Pharmaceuticals’ lead asset has hit all primary and secondary endpoints in a mid-stage study of age-related inflammation, setting the company up to begin phase 3 talks with the FDA.
MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-? Inhibitor MYMD-1® in Rheumatoid Arthritis
MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls